Legend Biotech shareholders back share plan amendment

The 2020 Restricted Shares Plan amendment received 279,130,008 votes for, 20,732,988 against and 30,336,686 abstentions.

Available on EDGAR 09/24/2026 - 04:00 PM EDT Accepted by SEC EDGAR 09/24/2026 - 04:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Legend Biotech Corporation held its 2026 annual general meeting on September 24, 2026, with approximately 330,199,682 ordinary shares, including those underlying ADSs, represented in person or by proxy. That was approximately 84.9% of the 388,976,826 ordinary shares issued and outstanding as of August 17, 2026. Shareholders voted on audited financial statements, ratification of Ernst & Young LLP as fiscal 2026 independent auditor, four Class III director elections, amendment and restatement of the 2020 Restricted Shares Plan, and authorization of directors and officers.

The plan amendment received 279,130,008 votes for, 20,732,988 against and 30,336,686 abstentions. The election tally for Robin Meng was 273,381,862 for and 56,768,390 against; Dr. Corazon D. Sanders received 326,472,036 votes for, Dr. Li Mao 328,120,942, and Dr. Peter Salovey 328,187,592.

Filing Explained

The AGM voting-results report and Exhibit 99.1 are incorporated by reference into the company’s Form F-3 and Form S-8 registration statements, unless later filings supersede them.

Key Figures

Shares represented: 330,199,682 ordinary shares Shares issued and outstanding: 388,976,826 ordinary shares Plan amendment votes for: 279,130,008 votes +3 more

6 metrics

Shares represented 330,199,682 ordinary shares Represented in person or by proxy at the September 24, 2026 annual general meeting

Shares issued and outstanding 388,976,826 ordinary shares As of August 17, 2026, the record date

Plan amendment votes for 279,130,008 votes Amendment and restatement of the 2020 Restricted Shares Plan

Plan amendment votes against 20,732,988 votes Amendment and restatement of the 2020 Restricted Shares Plan

Plan amendment abstentions 30,336,686 votes Amendment and restatement of the 2020 Restricted Shares Plan

Votes against Robin Meng 56,768,390 votes Class III director election

Key Terms

ordinary shares, ADSs, record date, incorporated by reference

4 terms

ordinary shares financial

"388,976,826 ordinary shares issued and outstanding"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

ADSs financial

"ordinary shares, including those underlying ADSs"

record date financial

"August 17, 2026, the record date"

The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.

incorporated by reference regulatory

"shall be deemed to be incorporated by reference"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares were represented at LEGN's 2026 annual meeting?

Approximately 330,199,682 ordinary shares, including those underlying ADSs, were represented in person or by proxy. This represented approximately 84.9% of the 388,976,826 ordinary shares issued and outstanding as of August 17, 2026.

How did LEGN shareholders vote on auditor ratification?

At the annual meeting, 329,955,758 votes were for ratifying Ernst & Young LLP as independent auditor for fiscal year 2026, 144,190 were against and 99,734 abstained.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

Date of Report: September 24, 2026

Commission File Number: 001-39307

Legend Biotech Corporation

(Exact Name of Registrant as Specified in its Charter)

77 Corporate Drive

Bridgewater, New Jersey 08807

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

On September 24, 2026, Legend Biotech Corporation (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “Meeting”). The voting results are attached hereto as Exhibit 99.1.

This report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference in the registration statements of the Company on Form F-3 (Nos. 333-257625 and 333-278050) and Form S-8 (Nos. 333-239478 and 333-283217), to the extent not superseded by documents or reports subsequently filed.

EXHIBITS

Exhibit 99.1 — Voting Results of Annual General Meeting

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	LEGEND BIOTECH CORPORATION
Date: September 24, 2026	By:	/s/ Ingrid Zhang
	Name:	Ingrid Zhang
	Title:	Chief Executive Officer

Exhibit 99.1

Voting Results of 2026 Annual General Meeting

At Legend Biotech Corporation’s (the “Company”) annual general meeting of shareholders held on September 24, 2026 (the “AGM”), the Company’s shareholders:

· received the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2025;

· ratified the appointment of Ernst & Young LLP as the Company’s independent auditor for the fiscal year ending December 31, 2026;

· re-elected each of Mr. Robin Meng, Dr. Corazon D. Sanders, Dr. Li Mao and Dr. Peter Salovey to serve as a Class III director for a three-year term;

· approved the amendment and restatement of the Company’s 2020 Restricted Shares Plan to increase the aggregate number of ordinary shares reserved for issuance by 19,100,000 ordinary shares; and

· authorized each of the directors and officers of the Company to take any and every action that might be necessary to effect the forgoing resolutions as such director or officer, in his or her absolute discretion, thinks fit.

A total of approximately 330,199,682 ordinary shares, including those underlying ADSs, representing approximately 84.9% of the 388,976,826 ordinary shares issued and outstanding as of August 17, 2026, the record date, were present in person or by proxy at the AGM. The results of the votes are as follows:

		For								Against								Abstain
Resolutions		Votes				%				Votes				%				Votes				%
Reception of Audited Financial Statements			329,998,122				84.837	%			110,480				0.028	%			91,080				0.023	%
Ratification of appointment of Ernst & Young LLP as Independent Auditor for Fiscal Year 2026			329,955,758				84.827	%			144,190				0.037	%			99,734				0.026	%
Election of Directors
Mr. Robin Meng (Class III)			273,381,862				70.282	%			56,768,390				14.594	%			49,430				0.013	%
Dr. Corazon D. Sanders (Class III)			326,472,036				83.931	%			3,681,710				0.947	%			45,936				0.012	%
Dr. Li Mao (Class III)			328,120,942				84.355	%			1,999,436				0.514	%			79,304				0.020	%
Dr. Peter Salovey (Class III)			328,187,592				84.372	%			1,967,750				0.506	%			44,340				0.011	%
Amendment and Restatement of 2020 Restricted Shares Plan			279,130,008				71.760	%			20,732,988				5.330	%			30,336,686				7.799	%
Authorization of Directors and Officers			328,624,268				84.484	%			1,441,908				0.371	%			133,506				0.034	%

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 19.1 KB